ArticleCureus2026
When Weight Loss Turns Dangerous: A Case Report of Tirzepatide-Induced Ketoacidosis in a Non-diabetic Woman.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tirzepatide has emerged as an effective therapeutic option for the management of obesity and type 2 diabetes mellitus because of its substantial benefits in weight reduction and glycemic control. Gastrointestinal adverse effects are common, whereas serious metabolic complications such as ketoacidosis remain rare. We describe the case of a woman in her early 30s with class II obesity who developed persistent vomiting, epigastric pain, and fatigue six days after her first tirzepatide injection. Laboratory investigations revealed mild hypoglycemia and high-anion-gap metabolic acidosis with markedly elevated ketone levels. Following an initial treatment in the emergency department (ED), she was admitted to the intensive care unit (ICU). She was managed with intravenous fluids, electrolytes, dextrose, and insulin, and she made a good recovery within 48 hours. The case highlights the potential life-threatening complications of dual incretin receptor agonists and the need to increase clinician awareness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.